Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC

Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.

You are being sent to the original publisher. FX Radar keeps this reference for market context and source discovery.